SCHEMBL456909

SCHEMBL456909

O=C1C(=NNC(=S)Nc2ccc(C(F)(F)F)cc2)Nc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
GAA P10253 2/20 0.43
KDR P35968 1/20 0.41
CDK1 P06493 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
EPHX2 P34913 2/20 0.39
HSPA9 P38646 2/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 2/20 0.38
SIRT2 Q8IXJ6 1/20 0.37
THRB P10828 1/20 0.37
MGAM O43451 1/20 0.37
SI P14410 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL455312 0.89 MAPT (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL2877863 0.87 ALDH1A1 (0.46) BCHEACHEMEN1KMT2ASMN1; SMN2
SCHEMBL2877739 0.85 MAPT (0.51) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL456579 0.83 ALDH1A1 (0.51) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL455238 0.82 RAB9A (0.44) SMN1; SMN2ALDH1A1MAPTGAANPC1
SCHEMBL455695 0.82 SLC2A1 (0.44) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL457421 0.82 LRRK2 (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL456608 0.82 CYP1A2 (0.49) BCHEMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL455700 0.81 ALDH1A1 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL456638 0.81 MAOA (0.34) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
EP-2240175-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) 2010-10-20 EP disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed